Partnership to develop variant proof COVID-19 vaccine - University of Sydney

The University of Sydney is a lead partner in an international consortium awarded US$19.3 million by The Coalition for Epidemic Preparedness Innovations to support the development of a 'variant-proof' SARS-CoV-2 vaccine candidate.

The multidisciplinary collaboration of Bharat Biotech International Ltd (Bharat Biotech), India, ExcellGene SA, Switzerland and the University of Sydney, Australia seeks to establish preclinical and … [+1435 chars]

full article...